Vimizim elosulfase alfa regulatory update

BioMarin said Brazil and Australia approved Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS IVA, Morquio’s syndrome), a rare inherited lysosomal storage disease. The recombinant human ...